文献速递造血干细胞移植与细胞治疗MDS 与骨髓增殖性肿瘤

伴遗传性髓系恶性肿瘤成人异基因造血干细胞移植的结局

Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies.
PubMed 文献 · Blood Adv · 2023-01-01

该研究纳入472例髓系肿瘤患者,其中26%携带有害胚系变异、34%接受了造血干细胞移植。携带有害胚系DDX41变异者严重急性移植物抗宿主病(GVHD)发生率为38%,高于CHEK2变异者(0%)、其他遗传性血液恶性肿瘤变异者(12%)及无此类胚系变异者(9%)(P=0.002)。移植后使用环磷酰胺可使DDX41相关髓系肿瘤患者严重急性GVHD风险降低(0% vs 53%,P=0.03)。

要点

  • 携带有害胚系DDX41变异的髓系肿瘤患者移植后严重急性GVHD发生率为38%。
  • 移植后使用环磷酰胺者严重急性GVHD发生率为0%,未使用者为53%(P=0.03)。
  • 作者主张DDX41变异者接受异基因造血干细胞移植时使用移植后环磷酰胺,即使供者为野生型。

核心结论

  • 携带有害胚系DDX41变异的髓系肿瘤患者异基因移植后严重急性GVHD发生率较高。
  • 移植后使用环磷酰胺可降低此类患者严重急性GVHD风险,作者主张在此类患者中应用移植后环磷酰胺。

研究设计与样本

  • 研究纳入472例髓系肿瘤患者,其中26%携带有害胚系变异,34%接受了造血干细胞移植。
  • 有害胚系CHEK2变异最常见于美国队列,有害胚系DDX41变异最常见于澳大利亚队列。

主要发现

  • 携带有害胚系DDX41变异者严重(3-4级)急性GVHD发生率为38%。
  • 携带有害胚系CHEK2变异者严重急性GVHD发生率为0%,其他遗传性血液恶性肿瘤变异者为12%,无此类胚系变异者为9%(P=0.002)。
  • 移植后使用环磷酰胺者严重急性GVHD发生率为0%,未使用者为53%(P=0.03)。

关键数值与推荐

  • 携带有害胚系DDX41变异者严重(3-4级)急性GVHD发生率为38%。
  • 携带有害胚系CHEK2变异者严重急性GVHD发生率为0%。
  • 其他遗传性血液恶性肿瘤变异者严重急性GVHD发生率为12%。
  • 无此类胚系变异者严重急性GVHD发生率为9%(P=0.002)。
  • 移植后使用环磷酰胺者严重急性GVHD发生率为0%,未使用者为53%(P=0.03)。

临床怎么用

  • 作者主张,携带有害胚系DDX41变异的个体因髓系恶性肿瘤接受异基因造血干细胞移植时使用移植后环磷酰胺,即使供者为野生型。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is increasing recognition that pathogenic germ line variants drive the development of hematopoietic cancers in many individuals. Currently, patients with hereditary hematologic malignancies (HHMs) receive similar standard therapies and hematopoietic stem cell transplant (HSCT) approaches as those with sporadic disease. We hypothesize that patients with myeloid malignancies and deleterious germ line predisposition variants have different posttransplant outcomes than those without such alleles. We studied 472 patients with myeloid neoplasms, of whom 26% had deleterious germ line variants and 34% underwent HSCT. Deleterious germ line variants in CHEK2 and DDX41 were most commonly seen in American and Australian cohorts, respectively. Patients with deleterious germ line DDX41 variants had a higher incidence of severe (stage 3-4) acute graft-versus-host disease (GVHD) (38%) than recipients with deleterious CHEK2 variants (0%), other HHM variants (12%), or patients without such germ line variants (9%) (P = .002). Importantly, the use of posttransplant cyclophosphamide reduced the risk of severe acute GVHD in patients receiving HSCT for deleterious germ line DDX41-associated myeloid neoplasms (0% vs 53%, P = .03). Based on these results, we advocate the use of posttransplant cyclophosphamide when individuals with deleterious germ line DDX41 variants undergo allogeneic HSCT for myeloid malignancies, even when transplantation has been performed using wild-type donors.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Saygin C, Roloff G, Hahn CN, et al. Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Adv. 2023. PMID: 36001442. doi:10.1182/bloodadvances.2022008172

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。